Incannex Healthcare Inc IXHL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.52
- Day Range
- $2.57–2.94
- 52-Week Range
- $1.96–12.68
- Bid/Ask
- $2.51 / $2.88
- Market Cap
- $45.87 Mil
- Volume/Avg
- 27,963 / 331,535
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 10
- Website
- https://www.incannex.com.au
Comparables
Valuation
|
Metric
|
IXHL
|
NYXH
|
OPCH
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 28.45 |
Price/Book Value | 2.12 | 3.28 | 3.68 |
Price/Sales | — | 66.58 | 1.22 |
Price/Cash Flow | — | — | 13.61 |
Price/Earnings
IXHL
NYXH
OPCH
Financial Strength
|
Metric
|
IXHL
|
NYXH
|
OPCH
|
|---|---|---|---|
Quick Ratio | 6.32 | 4.41 | 1.17 |
Current Ratio | 6.70 | 4.73 | 1.77 |
Interest Coverage | — | −216.64 | 8.00 |
Quick Ratio
IXHL
NYXH
OPCH
Profitability
|
Metric
|
IXHL
|
NYXH
|
OPCH
|
|---|---|---|---|
Return on Assets (Normalized) | −28.15% | −29.31% | 9.23% |
Return on Equity (Normalized) | −33.26% | −38.39% | 20.96% |
Return on Invested Capital (Normalized) | −29.94% | −34.27% | 13.01% |
Return on Assets
IXHL
NYXH
OPCH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Dplwzdwc | Zqyf | $73.0 Bil | |
MKKGY
| Merck KGaA ADR | Cwbmfcrrb | Fjvjcg | $69.8 Bil | |
HLN
| Haleon PLC ADR | Bfcxndcl | Fjmq | $37.8 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Wpsxwvv | Vfp | $14.6 Bil | |
VTRS
| Viatris Inc | Vscyzkjh | Cwfvp | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Zspjhtnt | Lfvt | $12.6 Bil | |
CTLT
| Catalent Inc | Dmwlqxfy | Jjfzkqc | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Ljqmvkz | Hct | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Bsmpyjmdv | Bdbcd | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Lsmjzlpy | Hxwtnn | $3.6 Bil |